Resistant cancer · One network
The intelligence layer for resistant cancer.
When cancer stops responding to treatment, every week counts. Cytogent gives every patient an intelligent agent that watches their journey, and connects hospitals with the drug developers working on what comes next.
- Patient-Level Agents
- Tumour-board preparation
- Trial options
- Anonymised insight
- Study requests
- Built for resistance
- European by design
- Data stays in the hospital
01The problem in three numbers
The science is moving. The connection is not.
8 in 10
Nearly 8 in 10 clinical trials miss their enrolment targets on schedule.
7%
Only about 7% of adults with cancer take part in treatment trials.
3 in 4
Nearly 3 in 4 oncologists feel overwhelmed by the pace of new treatments.
Each cell is one in a hundred
02The network
One platform.
Two sides. One goal.
For hospitals and clinicians
See resistance coming.
- A Patient-Level Agent for every enrolled patient
- Important changes flagged early
- Resistance anticipated before it surprises you
- Tumour-board documents prepared for you
- Trial options found for every willing patient
For drug developers and researchers
Find the right patients, earlier.
- Live insight into resistant-cancer populations
- Recommendations on what to study next
- Groups of patients ready for your study
- Forecasts of who will be eligible, where and when
- Apply to hospitals directly, with your full offer
03How it works
Connect. Understand. Act.
Three steps, no heavy lifting for your team.
- 01Inside the hospital
Connect
Cytogent connects securely to the hospital’s records. Data stays inside the hospital.
- 02One agent per patient
Understand
Every enrolled patient gets a Patient-Level Agent that follows their care and learns from the care team.
- 03Insight to action
Act
Clinicians get timely insight and trial options. Drug developers get the right patients and a clear next step.
Your expertise leads. Cytogent makes sure nothing is missed.
04Why Cytogent
Built for the moment treatment stops working.
Built for resistance
Not a general tool. Designed around the moment treatment stops working.
Learns from real practice
Every review by a clinician makes the system smarter for the next patient.
Sees ahead
We don’t only show who is eligible today; we anticipate who will be.
Neutral and European
Independent of any drug company or test lab, built for European privacy rules.
05Trust
Patient data never leaves the hospital without permission.
Sponsors see anonymised insight, never identities. Clinicians decide; Cytogent supports.
- Data stays in the hospital
- Anonymised insight only
- European privacy rules
- The clinician decides
Founding network · Europe
Join the network that puts resistant cancer first.
We are onboarding a founding group of cancer centres and research partners in Europe.
Questions
Quick answers.
What is Cytogent?
Cytogent is the intelligence layer for resistant cancer. It connects hospitals and drug developers around the moment a cancer stops responding to treatment: a Patient-Level Agent for every enrolled patient, and anonymised insight for the teams developing what comes next.
Who is Cytogent for?
Two sides of one network. Hospitals and clinicians who care for people with resistant cancer, and pharma, biotech, university and research teams who develop the therapies and studies that come next.
Does Cytogent replace clinical judgement?
No. The clinician always decides. Cytogent supports the care team by surfacing what matters, preparing documents and finding options.
Where does patient data go?
Patient data stays inside the hospital. Sponsors see anonymised insight, never identities, and contact with patients happens only through their own clinicians and with consent.
How do I join?
Tell us who you are on the Join page. We reply within two working days, set up a 30-minute call and walk you through the platform.